1. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT);Yamaguchi;Stroke,2006
2. Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients;Chao;Stroke,2014
3. B.J. Kim, M.K. Han, T.H. Park, S.S. Park, K.B. Lee, B.C. Lee, K.H. Yu, M.S. Oh, J.K. Cha, D.H. Kim, J. Lee, S.J. Lee, Y. Ko, J.M. Park, K. Kang, Y.J. Cho, K.S. Hong, J.T. Kim, J.C. Choi, D.E. Kim, D.I. Shin, W.J. Kim, J.S. Lee, B.W. Yoon, P.B. Gorelick, H.J. Bae, Low-versus standard-dose alteplase for ischemic strokes within 4.5 hours: a comparative effectiveness and safety study, Stroke 46(9) (2015) 2541–8.
4. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses;Liao;Stroke,2014
5. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study;Chao;Stroke,2010